Based on our analysis shown in Table 1 and 2, with ~1.2-5.1% of all breast cancers having an EGFR amplification, there would be ~ 1800-7650 patients whose tumor has EGFR amplification, with approximately half having a mutation in the PI3K pathway. The gene discussed is EGFR; the disease is neoplasm.